Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Takeda Treads Carefully With DPP-4 Late-Arrival Nesina, Plans Summer Launch

Executive Summary

Takeda’s beleaguered Nesina (alogliptin) becomes the fourth DPP-4 inhibitor approved by FDA for diabetes; it remains to be seen whether the drug can find its place in a highly competitive space that continues to be controlled by Merck’s first-to-market blockbuster Januvia.


Related Content

Takeda’s Global Ambitions Focus On Crohn’s, Cancer – And Churn
Diabetes, Asthma Portfolios Would Suit Risk-Sharing Contracts – Express Scripts
Alogliptin, Saxagliptin Show Neutral CV Effects In Outcomes Studies
Amgen Makes Second Big Move in China With New R&D Center That Will Tap Into Chinese University
Will CV Verdicts For Onglyza, Nesina Cause FDA To Change Its Tune On Antidiabetic Safety?
Orexigen Defines A Way To Get The Contrave PDUFA Clock Ticking
Riding High, Victoza Hopes To Gain Ground Over Popular DPP-4s With Label Change
Takeda Re-Files DPP-4 Inhibitor Alogliptin, Plays Up Combo With Actos
Boehringer/Lilly's Linagliptin Approved: Can Renal Flexibility Unlock The DPP-4 Market?
Anatomy Of The Avandia Decision: FDA’s Woodcock Splits The Difference Between OND, OSE Views


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts